Hill Island Financial LLC Makes New Investment in Eli Lilly and Company $LLY

Hill Island Financial LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, HoldingsChannel reports. The fund purchased 437 shares of the company’s stock, valued at approximately $341,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. PNC Financial Services Group Inc. lifted its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. raised its position in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP lifted its stake in Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after purchasing an additional 682,203 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $4,613,912,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 2.5%

NYSE LLY opened at $840.46 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $795.47 billion, a P/E ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The stock has a 50 day simple moving average of $734.60 and a two-hundred day simple moving average of $765.98. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on LLY shares. Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. JPMorgan Chase & Co. lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $938.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.